Author: admin

Peripheral Arterial Disease Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | Novo Nordisk, Takeda, Ixaka, Humacyte, Proteon Therapeutics, ReNeuron Limited

“Delveinsight Business Research LLP”
DelveInsight’s “Peripheral Arterial Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Peripheral Arterial Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Peripheral Arterial Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Peripheral Arterial Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Peripheral Arterial Disease: An Overview

Peripheral artery disease (PAD) is a common manifestation of arterial stenosis of the lower and/or upper extremities that reduces arterial flow. It is well known that Peripheral Arterial Disease is associated with elevated morbidity and mortality with cardiovascular (CV) disease.

In Peripheral Arterial Disease, the legs or arms—usually the legs—do not receive enough blood flow to keep up with the demand, which may cause leg pain when walking (claudication) and other symptoms. Many people with Peripheral Arterial Disease have no symptoms. The most common symptom of lower-extremity Peripheral Arterial Disease is painful muscle cramping in the hips, thighs, or calves when walking, climbing stairs, or exercising. However, those who develop a painful ache in their legs when they walk usually disappear after a few minutes of rest. The medical term for this is “intermittent claudication”.

Physical examination of the legs for symptoms like shiny skin, brittle toenails, hair loss on legs and feet, and leg ulcers are evaluated for the diagnosis of Peripheral Arterial Disease. The ankle-brachial pressure index (ABPI) test is widely used to diagnose Peripheral Arterial Disease. Further testing, like an ultrasound scan or an angiogram, is done when there is uncertainty about the diagnosis.

There is no cure for Peripheral Arterial Disease, but lifestyle changes and medicine can help reduce the symptoms. Medications called statins are commonly prescribed. If Peripheral Arterial Disease is so far progressed and does not respond to noninvasive therapies such as lifestyle changes, medication, or both, surgery may be necessary.

Peripheral Arterial Disease Market Key Facts

  • The total market size of Peripheral Arterial Disease in the US was approximately USD 2559 million in 2022.

  • In 2022, EU4 and the UK countries captured an approximately estimated USD 989 million.

  • Among EU4 and the UK, Germany consistently captured the highest market, with approximately USD 397 million in 2022.

  • Among the 7MM, Japan represented approximately 10% of the total market of Peripheral Arterial Disease with USD 382 million in 2022.

  • In 7MM, there were approximately 17,245,750, diagnosed prevalent cases of Peripheral Arterial Disease in 2022, which are expected to increase at a significant CAGR by 2032.

  • The US accounted for approximately 9,505,662 cases, which was the highest diagnosed prevalent cases of Peripheral Arterial Disease, followed by EU4 and the UK with 5,906,659 cases, and Japan with 1,833,429 cases in 2022. These cases are expected to increase in the US, EU4, the UK, and Japan by 2032.

  • Among the European countries, Germany had the highest diagnosed prevalent population of Peripheral Arterial Disease (approximately 2,371,290 cases), followed by Italy (1,023,681 cases) in 2022. On the other hand, Spain (767,393 cases) had the lowest diagnosed prevalent population in EU4 and the UK countries and the 7MM.

Peripheral Arterial Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Peripheral Arterial Disease pipeline therapies. It also thoroughly assesses the Peripheral Arterial Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Peripheral Arterial Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Peripheral Arterial Disease Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Peripheral Arterial Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Peripheral Arterial Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Peripheral Arterial Disease Epidemiology, Segmented as –

  • Total Diagnosed Prevalent Cases of Peripheral Arterial Disease in the 7MM [2019–2032]

  • Age-specific Diagnosed Prevalent Cases of Peripheral Arterial Disease in the 7MM [2019–2032]

  • Severity-specific Diagnosed Prevalent Cases of Peripheral Arterial Disease in the 7MM [2019–2032]

  • Gender-specific Diagnosed Prevalent Cases of Peripheral Arterial Disease in the 7MM [2019–2032]

Peripheral Arterial Disease Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Peripheral Arterial Disease market or expected to be launched during the study period. The analysis covers the Peripheral Arterial Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Peripheral Arterial Disease drugs based on their sale and market share.

The report also covers the Peripheral Arterial Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Peripheral Arterial Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Peripheral Arterial Disease Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-market

Peripheral Arterial Disease Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Peripheral Arterial Disease. Currently, Novo Nordisk is leading the therapeutics market with its Peripheral Arterial Disease drug candidates in the most advanced stage of clinical development.

Peripheral Arterial Disease Companies Actively Working in the Therapeutics Market Include

  • Novo Nordisk

  • Takeda

  • Mercator MedSystems, Inc.

  • Beijing Northland Biotech. Co., Ltd.

  • Ixaka Ltd

  • Humacyte, Inc.

  • CardioVascular BioTherapeutics

  • Proteon Therapeutics

  • ReNeuron Limited

  • Alucent Biomedical

  • Athersys

  • ARCA biopharma

  • Ambulero

  • Venturis Therapeutics

And Many Others

Emerging and Marketed Peripheral Arterial Disease Therapies Covered in the Report Include:

  • Semaglutide: Novo Nordisk

  • VM202: Helixmith

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Peripheral Arterial Disease Competitive Intelligence Analysis

4. Peripheral Arterial Disease Market Overview at a Glance

5. Peripheral Arterial Disease Disease Background and Overview

6. Peripheral Arterial Disease Patient Journey

7. Peripheral Arterial Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Peripheral Arterial Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Peripheral Arterial Disease Unmet Needs

10. Key Endpoints of Peripheral Arterial Disease Treatment

11. Peripheral Arterial Disease Marketed Therapies

12. Peripheral Arterial Disease Emerging Drugs and Latest Therapeutic Advances

13. Peripheral Arterial Disease Seven Major Market Analysis

14. Attribute Analysis

15. Peripheral Arterial Disease Market Outlook (In US, EU5, and Japan)

16. Peripheral Arterial Disease Companies Active in the Market

17. Peripheral Arterial Disease Access and Reimbursement Overview

18. KOL Views on the Peripheral Arterial Disease Market

19. Peripheral Arterial Disease Market Drivers

20. Peripheral Arterial Disease Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/peripheral-arterial-disease-pad-pulmonary-vascular-disease-pvd-market

 

 

Other Trending Healthcare Reports by DelveInsight

Dermal Regeneration Matrix Market

“Dermal Regeneration Matrix Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Dermal Regeneration Matrix market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Dermal Regeneration Matrix market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Peripheral Arterial Disease Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | Novo Nordisk, Takeda, Ixaka, Humacyte, Proteon Therapeutics, ReNeuron Limited

Head and Neck Cancer Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – Estimates DelveInsight | Debiopharm, Merck, AstraZeneca, MedImmune, Eisai, Merck, Kura Oncology

“Delveinsight Business Research LLP”
The Head and Neck Cancer Market in the 7MM was observed to be USD 2,801 million in 2021, which is expected to grow by 2032. As per DelveInsight, the Head and Neck Cancer Market is anticipated to evolve immensely in the coming years owing to the increase in the patient pool and the expected entry of emerging therapies.

DelveInsight’s “Head and Neck Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Head and Neck Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Head and Neck Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Head and Neck Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Head and Neck Cancer: An Overview

Head and Neck Cancer (HNC) usually begins in the squamous cells – often referred to as squamous cell carcinomas of the head and neck – that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box. They can also begin in the salivary glands, sinuses, muscles, or nerves, but they are less common than squamous cell carcinomas. HNC begins in several places in the head and throat, excluding brain or eye cancer.

The types of HNC include laryngeal cancer, nasopharyngeal cancer, hypopharyngeal cancer, nasal cavity and paranasal sinus cancer, salivary gland cancer, oral cancer, oropharyngeal cancer, and tonsil cancer. Histologically, progression to invasive HNSCC follows an ordered series beginning with epithelial cell hyperplasia, followed by dysplasia (mild, moderate, and severe), carcinoma in situ, and invasive carcinoma.

Symptoms of HNC include a lump in the neck or a sore in the mouth or throat that does not heal, a persistent sore throat, difficulty swallowing, and a change or hoarseness in the voice. Other, less dangerous illnesses can also cause these symptoms.

There are many tests used for diagnosing HNC- physical examination/blood and urine tests, endoscopy, biopsy, biomarker testing of the tumor, X-ray/barium swallow, panoramic radiograph, ultrasound, magnetic resonance imaging, bone scan, etc.

Head and Neck Cancer Market Key Facts

  • The Head and Neck Cancer market size in the 7MM was observed to be USD 2,801 million in 2021.

  • In 2021, the Head and Neck Cancer market size in the US was USD 1,831 million. 

  • Among the EU-5 countries, Germany had the highest Head and Neck Cancer market size in 2021, i.e., USD 219 million. The lowest Head and Neck Cancer market size was estimated in Italy, with USD 114 million in 2021.

  • In Japan, the Head and Neck Cancer market size was observed to be USD 187 million in 2021.

  • In 2021, the total Head and Neck Cancer incident cases in the 7MM countries were ~158,000.

  • Among the European countries, Germany had the highest number of incident cases of Head and Neck Cancer in 2021, i.e., ~20,000 cases, followed by France which had ~16,000 incident cases in 2021. On the other hand, Italy had the lowest number of incident cases of Head and Neck Cancer, i.e. ~9900 cases in 2021. Japan had ~20,000 incident cases of HNC in 2021.

Head and Neck Cancer Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Head and Neck Cancer pipeline therapies. It also thoroughly assesses the Head and Neck Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Head and Neck Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Head and Neck Cancer Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Head and Neck Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Head and Neck Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Head and Neck Cancer Epidemiology, Segmented as –

  • Total Incident Cases of Head and Neck Cancer in the 7MM 

  • Molecular Alteration-specific Incident Cases of Head and Neck Cancer in the 7MM 

  • Stage-specific Incident Cases of Head and Neck Cancer in the 7MM 

  • Site-specific Incident Cases of Head and Neck Cancer in the 7MM 

  • HPV-specific Incident Cases of Head and Neck Cancer scenario in the 7MM 

Head and Neck Cancer Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Head and Neck Cancer market or expected to be launched during the study period. The analysis covers the Head and Neck Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Head and Neck Cancer drugs based on their sale and market share.

The report also covers the Head and Neck Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Head and Neck Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Head and Neck Cancer Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market

Head and Neck Cancer Therapeutics Analysis

Among all the available therapeutic options, chemotherapy is being extensively used in all lines of treatment. Multiple drugs have been identified with the advancement of medical technologies and increased research and development activities. Immunotherapeutic options have also been identified for treating HNC patients.

Overall, the treatment approach for Head and Neck Cancer (HNC) patients can involve multiple options like surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Pharmacological therapies are mainly used to destroy cancer cells, and they are either administered systematically or locally (by a medical oncologist). Pharmacological therapies being administered to a HNC patient can be chemotherapy, targeted therapy, or immunotherapy.

In November 2011, the US FDA approved cetuximab (ERBITUX) in combination with chemotherapy for the first time for the treatment of Head and Neck Cancer (HNC) patients. The FDA approved pembrolizumab (KEYTRUDA) for the first-line treatment of patients with metastatic or unresectable recurrent HNSCC in June 2019. In April 2017, Bristol-Myers Squibb announced the approval of nivolumab (OPDIVO) as monotherapy for the treatment of SCCHN in adults.

Several major pharma and biotech companies are developing therapies for Head and Neck cancer. Currently, Innate Pharma is leading the therapeutics market with its Head and Neck cancer drug candidates in the most advanced stage of clinical development.

Head and Neck Cancer Companies Actively Working in the Therapeutics Market Include

Some of the key companies in the Head and Neck Cancer Companies Market include Debiopharm, Merck, AstraZeneca, MedImmune, Eisai Co Ltd/Merck & Co, Kura Oncology, Cellectar Biosciences, Galera Therapeutics, Inc., BioMimetix JV, LLC, Bristol-Myers Squibb, QBiotics Group Limited, Alentis Therapeutics AG, Coordination Pharmaceuticals, Inc., Genmab, Merck Sharp & Dohme LLC, Immunovative Therapies, Ltd., TyrNovo Ltd, BioNTech SE, Aveta Biomics, Inc., Pfizer, and Cue Biopharma, and other.

Emerging and Marketed Head and Neck Cancer Therapies Covered in the Report Include:

  • Durvalumab: AstraZeneca

  • Tipifarnib : Kura Oncology

  • Iopofosine: Cellectar Biosciences

  • TECENTRIQ (Atezolizumab): Hoffmann-La Roche

  • KEYTRUDA (pembrolizumab): Merck Sharp & Dohme

  • XEVINAPANT (debio 1143): Merck KGaA

  • Toripalimab: Junshi Biosciences/Coherus

  • Tipifarnib: Kura Oncology

And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Head and Neck Cancer Competitive Intelligence Analysis

4. Head and Neck Cancer Market Overview at a Glance

5. Head and Neck Cancer Disease Background and Overview

6. Head and Neck Cancer Patient Journey

7. Head and Neck Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Head and Neck Cancer Treatment Algorithm, Current Treatment, and Medical Practices

9. Head and Neck Cancer Unmet Needs

10. Key Endpoints of Head and Neck Cancer Treatment

11. Head and Neck Cancer Marketed Therapies

12. Head and Neck Cancer Emerging Drugs and Latest Therapeutic Advances

13. Head and Neck Cancer Seven Major Market Analysis

14. Attribute Analysis

15. Head and Neck Cancer Market Outlook (In US, EU5, and Japan)

16. Head and Neck Cancer Companies Active in the Market

17. Head and Neck Cancer Access and Reimbursement Overview

18. KOL Views on the Head and Neck Cancer Market

19. Head and Neck Cancer Market Drivers

20. Head and Neck Cancer Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/head-and-neck-cancer-hnc-market

 

 

Other Trending Healthcare Reports by DelveInsight

Epstein Barr virus (EBV) Market

“Epstein Barr virus (EBV) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Epstein Barr virus (EBV) market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Epstein Barr virus (EBV) market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Head and Neck Cancer Market Poised for Phenomenal Expansion During the Forecast Period (2023-32) – Estimates DelveInsight | Debiopharm, Merck, AstraZeneca, MedImmune, Eisai, Merck, Kura Oncology

Angelman Syndrome Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Estimates DelveInsight | Neuren, Ultragenyx, Ionis Pharma, Roche, GEXVal, PTC Therapeutics

“Delveinsight Business Research LLP”
DelveInsight’s “Angelman Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Angelman Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Angelman Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Angelman Syndrome treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Angelman Syndrome: An Overview

According to the National Organization for Rare Disorders, Angelman syndrome is a rare genetic and neurological disorder characterized by severe developmental delay and learning disabilities; absence or near absence of speech; inability to coordinate voluntary movements (ataxia); tremulousness with jerky movements of the arms and legs and a distinct behavioral pattern characterized by a happy disposition and unprovoked episodes of laughter and smiling.

People with Angelman syndrome have developmental problems that become noticeable by the age of 6 – 12 months. Other common signs and symptoms usually appear in early childhood like walking and balance disorders, gastrointestinal issues, seizures, and little to no speech. It is typically caused by a deletion or mutation of the UBE3A gene on chromosome 15, which leads to a lack of functional UBE3A protein in the brain.

A diagnosis of Angelman syndrome may be made based on a detailed patient history, a thorough clinical evaluation, and the identification of characteristic findings. About 80% of cases can be confirmed through a variety of specialized blood tests such as DNA methylation. Fluorescent in situ hybridization (FISH) or, most commonly, microarray chromosome analysis can detect the characteristic deletion of chromosome 15q11-q13 in cells of the body.

Angelman Syndrome Market Key Facts

  • According to the Angelman Syndrome Foundation (2022), Angelman syndrome is a rare neuro-genetic disorder that occurs in one in 15,000 live births or 500,000 people worldwide. It is caused by a loss of function of the UBE3A gene in the 15th chromosome derived from the mother.

  • As per Angelman UK (2022), Angelman Syndrome is a rare neurological disorder affecting around 1:20,000 births. Characteristic features include delayed development, severe learning difficulties, little or no speech, and issues with movement and balance.

  • In a study by the National Institutes of Health Rare Diseases Clinical Research Network Angelman Syndrome Natural History Study (2010), the most common behavioral findings in AS patients were mouthing behavior (95%), short attention span (92%), ataxic or broad-based gait (88%), history of sleep difficulties (80%), and fascination with water (75%).

  • According to the National Organization for Rare Disorders (2022), Angelman syndrome affects males and females in equal numbers. The prevalence of Angelman syndrome is estimated to be approximately 1 in 12,000-20,000 people in the general population.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Angelman Syndrome pipeline therapies. It also thoroughly assesses the Angelman Syndrome market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Angelman Syndrome drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Angelman Syndrome Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Angelman Syndrome epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Angelman Syndrome epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Angelman Syndrome Epidemiology, Segmented as –

  • Total Prevalent cases of Angelman Syndrome in the 7MM [2019–2032]

  • Diagnosed Prevalent Cases of Angelman Syndrome in the 7MM [2019–2032]

  • Angelman Syndrome Associated with Clinical Manifestations in the 7MM [2019–2032]

  • Treated Cases of Angelman Syndrome in the 7MM [2019–2032]

Angelman Syndrome Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Angelman Syndrome market or expected to be launched during the study period. The analysis covers the Angelman Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Angelman Syndrome drugs based on their sale and market share.

The report also covers the Angelman Syndrome pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Angelman Syndrome companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Angelman Syndrome Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/angelman-syndrome-market-forecast

Angelman Syndrome Therapeutics Analysis

There is no specific therapy for Angelman syndrome at this time. The best treatment is to minimize seizures, anxiety, and gastrointestinal issues and maximize sleep. Thus, the management of Angelman syndrome requires a multidisciplinary approach involving pediatricians, neurologists, geneticists, speech therapists, occupational therapists, physical therapists, and behavioral specialists. Seizures are treated with medications and dietary therapies, while sleep issues are treated with medications and sleep training.

Since the treatment landscape is devoid of any effective curative treatment options, any significant development in this direction is expected to create a tectonic impact on the existing market scenario. Several major pharma and biotech companies are developing therapies for Angelman Syndrome. Some of the drugs in the pipeline include GTX-102 (GeneTx Biotherapeutics/Ultragenyx Pharmaceutical), ION582 (Ionis Pharmaceuticals/Biogen/Emmes Company), and NNZ-2591 (Neuren Pharmaceuticals), among others. Currently, Neuren Pharmaceuticals is leading the therapeutics market with its Angelman Syndrome drug candidates in the most advanced stage of clinical development.

Angelman Syndrome Companies Actively Working in the Therapeutics Market Include

  • Neuren Pharmaceuticals

  • Ultragenyx Pharmaceutical

  • Ionis Pharmaceuticals

  • Roche

  • GEXVal

  • PTC Therapeutics

  • Taysha Gene Therapies

  • Ovid Therapeutics

  • GeneTX Biotherapeutics, LLC

  • Ultragenyx Pharmaceutical Inc

  • Hoffmann-La Roche

  • Ovid Therapeutics Inc.

  • Biogen

And Many Others

Emerging and Marketed Angelman Syndrome Therapies Covered in the Report Include:

  • GT-AS: PTC Therapeutics

  • GXV 001: GEXVal

  • RG 6091: Roche

  • GTX-102: GeneTx Biotherapeutics/Ultragenyx Pharmaceutical

  • ION582: Ionis Pharmaceuticals/Biogen/Emmes Company

  • NNZ-2591: Neuren Pharmaceuticals

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/angelman-syndrome-market-forecast

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Angelman Syndrome Competitive Intelligence Analysis

4. Angelman Syndrome Market Overview at a Glance

5. Angelman Syndrome Disease Background and Overview

6. Angelman Syndrome Patient Journey

7. Angelman Syndrome Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Angelman Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Angelman Syndrome Unmet Needs

10. Key Endpoints of Angelman Syndrome Treatment

11. Angelman Syndrome Marketed Therapies

12. Angelman Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Angelman Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Angelman Syndrome Market Outlook (In US, EU5, and Japan)

16. Angelman Syndrome Companies Active in the Market

17. Angelman Syndrome Access and Reimbursement Overview

18. KOL Views on the Angelman Syndrome Market

19. Angelman Syndrome Market Drivers

20. Angelman Syndrome Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/angelman-syndrome-market-forecast

 

 

 Other Trending Healthcare Reports by DelveInsight

Cardiovascular Calcification Market

“Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Cardiovascular Calcification market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Cardiovascular Calcification market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Angelman Syndrome Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Estimates DelveInsight | Neuren, Ultragenyx, Ionis Pharma, Roche, GEXVal, PTC Therapeutics

Common Warts Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) – Estimates DelveInsight | Aclaris, Kino Pharma, KinoPharma, Maruho, Nielsen BioSciences, Phio Pharma

“Delveinsight Business Research LLP”
DelveInsight’s “Common Warts Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Common Warts market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Common Warts drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Common Warts treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Common Warts: An Overview

Common warts, also known as verruca vulgaris, are caused by nonmalignant strains of human papillomavirus (HPV). Common warts are small, grainy skin growths that often occur on fingers or hands. Rough to the touch, common warts also often feature a pattern of tiny black dots, which are small, clotted blood vessels. It can take a wart as long as two to six months to develop after your skin has been exposed to the virus.

Common warts are easy to distinguish from other types of warts, such as genital, filiform, and plantar warts. They are most commonly found on the hands or fingers, though they can also be found on the knees, ankles, arms, and legs. The majority of warts are asymptomatic. They do, however, produce facial deformity and, in a small percentage of cases, regional discomfort.

Common Warts Market Key Facts

  • As per DelveInsight, the market size of Common Warts in the seven major markets was found to be USD 720.03 million in 2020, which is expected to grow by 2032. 

  • The total 7MM prevalent cases of Common Warts were 14,900,000+ in 2020.

  • Some of the key companies in the Common Warts market include Nielsen BioSciences, Veloce BioPharma, Verrica Pharmaceutical, Aclaris Therapeutics, KinoPharma, and others.

Common Warts Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Common Warts pipeline therapies. It also thoroughly assesses the Common Warts market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Common Warts drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Common Warts Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Common Warts epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Common Warts epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Common Warts Epidemiology, Segmented as –

  • Total Diagnosed Prevalent Cases of Common Warts in the 7MM [2019–2032]

  • Gender-specific Diagnosed Prevalent Cases of Common Warts in the 7MM [2019–2032]

Common Warts Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Common Warts market or expected to be launched during the study period. The analysis covers the Common Warts market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Common Warts drugs based on their sale and market share.

The report also covers the Common Warts pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Common Warts companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Common Warts Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/common-warts-market

Common Warts Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Common Warts. Currently, X4 Pharmaceuticals is leading the therapeutics market with its Common Warts drug candidates in the most advanced stage of clinical development.

Common Warts Companies Actively Working in the Therapeutics Market Include

  • Aclaris Therapeutics, Inc.

  • Kino Pharma

  • KinoPharma, Inc.

  • Maruho Co., Ltd

  • Nielsen BioSciences

  • Phio Pharmaceuticals

  • Veloce BioPharma

  • Verrica Pharmaceutical

  • X4 Pharmaceuticals

And many others

Emerging and Marketed Common Warts Therapies Covered in the Report Include:

  • A-101: Aclaris Therapeutics, Inc.

  • Candin: Nielsen BioSciences

  • CLS006: Maruho Co., Ltd.

  • FIT039: KinoPharma

  • Mavorixafor: X4 Pharmaceuticals

  • VBP-245: Veloce BioPharma

  • VP-102: Verrica Pharmaceutical

And many more

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/common-warts-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Common Warts Competitive Intelligence Analysis

4. Common Warts Market Overview at a Glance

5. Common Warts Disease Background and Overview

6. Common Warts Patient Journey

7. Common Warts Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Common Warts Treatment Algorithm, Current Treatment, and Medical Practices

9. Common Warts Unmet Needs

10. Key Endpoints of Common Warts Treatment

11. Common Warts Marketed Therapies

12. Common Warts Emerging Drugs and Latest Therapeutic Advances

13. Common Warts Seven Major Market Analysis

14. Attribute Analysis

15. Common Warts Market Outlook (In US, EU5, and Japan)

16. Common Warts Companies Active in the Market

17. Common Warts Access and Reimbursement Overview

18. KOL Views on the Common Warts Market

19. Common Warts Market Drivers

20. Common Warts Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/common-warts-market

 

 

Other Trending Healthcare Reports by DelveInsight 

Glabellar Frown Lines Market

“Glabellar Frown Lines Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Glabellar Frown Lines market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Glabellar Frown Lines market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Common Warts Market Set to Experience Unprecedented Growth During the Forecast Period (2023-32) – Estimates DelveInsight | Aclaris, Kino Pharma, KinoPharma, Maruho, Nielsen BioSciences, Phio Pharma

Type 1 Diabetes Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | Amytrx, Anelixis, Arecor, AstraZeneca, Eli Lilly, Histogen, ImCyse, Kamada

“Delveinsight Business Research LLP”
DelveInsight’s “Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Type 1 Diabetes market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Type 1 Diabetes drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Type 1 Diabetes treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Type 1 Diabetes: An Overview

Diabetes is a chronic metabolic condition characterized by high or low blood glucose (or blood sugar) levels, leading to significant damage to the heart, blood vessels, eyes, kidneys, and nerves over time. The rationale behind developing diabetes incorporates two factors: insufficient insulin production (produced by the pancreas and reduced blood glucose) or unsatisfactory cell response to insulin action.

Clinically, diabetes is classified into three types, type 1 diabetes (TD-1), Type 1 Diabetes (TD2), and gestation diabetes. TD-1 is the consequence of an autoimmune reaction that causes the pancreas to suppress insulin-producing β-cells and leads to severe insulin deficiency. TD2 is linked with a genetic factor, which is far more common and substantially correlates with obesity and unhealthy lifestyles. Insulin resistance (inadequate reaction of peripheral cells to insulin) and pancreatic β-cell dysfunction (impaired insulin secretion) are marked by Type 1 Diabetes, leading to relative insulin deficiency.

Type 1 diabetes is the most common type of diabetes among children, however, type 1 diabetes can occur at any age. Generally considered 5-10% of the diabetes patient pool. The typical symptoms of type 1 diabetes include excessive thirst, blurred vision, dry mouth, upset stomach and vomiting, bedwetting, frequent urination, unexplained weight loss, fatigue, labored breathing, lack of energy, and constant hunger. In patients having extreme type 1 diabetes, the symptoms include a fruity odor to the breath, belly pain, and rapid breathing.

As per DelveInsight, the Type 1 Diabetes therapeutics market is anticipated to evolve immensely in the coming years owing to the increasing prevalent population of Diabetes, increased healthcare spending worldwide, and the expected launch of emerging drugs in the market. Currently, key players such as Provention Bio, Oramed, Eli Lilly, Novo Nordisk, REMD Biotherapeutics, and several others are actively working in the Type 1 Diabetes therapeutics market.

Type 1 Diabetes Market Key Facts

  • According to the National Diabetes Statistics Report (2020), 34.2 million people in the United States have diabetes in 2018, accounting for 10.5% of the total population.

  • According to the Centers for Disease Control and Prevention (2020), 28.7 million people of all ages, or 8.7% of the US population, were diagnosed with diabetes in 2019. 283,000 children and adolescents younger than age 20 years or 35 per 10,000 US youths have been diagnosed of diabetes. This includes 244,000 with type 1 diabetes, accounting for 10.5% of the total population.

  • As per The Ministry of Health, Labor and Welfare (2020), reported that 14.5% of the Japanese population was strongly suspected of having diabetes (A1C 6.5% or higher or treated for diabetes).

  • As per the German Diabetes Society (2022), about 341,000 people in Germany have type 1 diabetes. 

  • As per the National Diabetes Statistics Report (2020), 210,000 children and adolescents under the age of 20 in the United States were diagnosed with diabetes in 2018, of which 187,000 people had type 1 diabetes diagnosis. By the coming year, these cases are expected to increase).’

‘

Type 1 Diabetes Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Type 1 Diabetes pipeline therapies. It also thoroughly assesses the Type 1 Diabetes market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Type 1 Diabetes drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Type 1 Diabetes Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Type 1 Diabetes epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Type 1 Diabetes epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Type 1 Diabetes Epidemiology, Segmented as –

  • Total Prevalent Cases of Type 1 Diabetes 

  • Treated cases of Type 1 Diabetes

  • Total diagnosed prevalent cases of Type 1 diabetes

  • Total age-specific prevalent diagnosed cases of Type 1 Diabetes 

  • Total gender-specific prevalent diagnosed cases of Type 1 Diabetes

Type 1 Diabetes Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Type 1 Diabetes market or expected to be launched during the study period. The analysis covers the Type 1 Diabetes market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Type 1 Diabetes drugs based on their sale and market share.

The report also covers the Type 1 Diabetes pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Type 1 Diabetes companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Type 1 Diabetes Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/type-1-diabetes-market

Type 1 Diabetes Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Type 1 Diabetes. Currently, Provention Bio is leading the therapeutics market with its Type 1 Diabetes drug candidates in the most advanced stage of clinical development.

Type 1 Diabetes Companies Actively Working in the Therapeutics Market Include

Adocia, Amytrx, Anelixis Therapeutics, Arecor, AstraZeneca, Avotres, Bioprojet, Diamyd Medical, Dompe Pharmaceutical, Eli Lilly, Gan&Lee Pharmaceuticals, Histogen, ImCyse, Kamada, Landos Biopharma, Novartis, Novo Nordisk, Oramed, Panbela Therapeutics, Precigen ActoBiotics, Prevention Bio, REMD Biotherapeutics, TikoMed, Tolerion, Vertex Pharmaceuticals, Zealand Pharma, and many others.

Emerging and Marketed Type 1 Diabetes Therapies Covered in the Report Include:

  • AG019: Precigen ActoBiotics

  • AMTX 100: Amytrx

  • Basal insulin-Fc: Eli Lilly

  • Emricasan: Histogen

  • IMCY-0098: ImCyse

  • Insulin icodec: Novo Nordisk

  • Iscalimab: Novartis

  • Ladarixin: Dompe Pharmaceutical

  • LY3209590: Eli Lilly and Company Therapeutics

  • MHS552: Novartis

  • NNC0471-0119: Novo Nordisk

  • ORMD-0801: Oramed

  • Teplizumab: Prevention Bio

  • Volagidemab: REMD Biotherapeutics

  • VX-880: Vertex Pharmaceuticals

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

https://www.delveinsight.com/sample-request/type-1-diabetes-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Type 1 Diabetes Competitive Intelligence Analysis

4. Type 1 Diabetes Market Overview at a Glance

5. Type 1 Diabetes Disease Background and Overview

6. Type 1 Diabetes Patient Journey

7. Type 1 Diabetes Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Type 1 Diabetes Treatment Algorithm, Current Treatment, and Medical Practices

9. Type 1 Diabetes Unmet Needs

10. Key Endpoints of Type 1 Diabetes Treatment

11. Type 1 Diabetes Marketed Therapies

12. Type 1 Diabetes Emerging Drugs and Latest Therapeutic Advances

13. Type 1 Diabetes Seven Major Market Analysis

14. Attribute Analysis

15. Type 1 Diabetes Market Outlook (In US, EU5, and Japan)

16. Type 1 Diabetes Companies Active in the Market

17. Type 1 Diabetes Access and Reimbursement Overview

18. KOL Views on the Type 1 Diabetes Market

19. Type 1 Diabetes Market Drivers

20. Type 1 Diabetes Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/type-1-diabetes-market

 

 

Other Trending Healthcare Reports by DelveInsight

Goitre Market

“Goitre Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Goitre market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Goitre market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Type 1 Diabetes Market: Latest Study by DelveInsight Forecasts Remarkable Growth During the Forecast Period (2023-32) | Amytrx, Anelixis, Arecor, AstraZeneca, Eli Lilly, Histogen, ImCyse, Kamada

Ascites Market is expected to grow by 2032, estimates DelveInsight

DelveInsight’s Ascites Market Insights report includes a comprehensive understanding of current treatment practices, ascites emerging drugs, market share of individual therapies, and current and forecasted ascites market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

 

Key Takeaways from the Ascites Market Report

  • According to DelveInsight’s analysis, the market size for ascites across the 7MM is expected to grow with a significant CAGR by 2032.
  • DelveInsight’s analysis reveals that the overall cases of ascites due to cirrhosis in the 7MM was reported as ~244K in 2022. 
  • Assessments as per DelveInsight’s analysts showed that there were  27K cases of Grade I ascites due to cirrhosis in the United States in 2022 which was nearly 22% of all grade ascites cases.
  • Prominent companies working in the domain of ascites, including Ocelot Bio, Inc., PharmaIN, Grifols Therapeutics LLC, and others, are actively working on innovative drugs for Ascites. These novel ascites therapies are anticipated to enter the ascites market in the forecast period and are expected to change the market.
  • Some of the key therapies for ascites treatment include OCE-205, PHIN-214 Subcutaneous injection, Albutein 20% Injectable Solution, and others. 

 

Discover which therapies are expected to grab the ascites market share @ Ascites Market Size Report

 

Ascites Overview

Ascites is characterized by an abnormal accumulation of fluid within the peritoneal cavity, leading to the collection of fluid in the abdominal spaces. When ascites becomes severe, it can cause discomfort and hinder the patient’s ability to move comfortably. Additionally, it has the potential to pave the way for abdominal infections and may result in the movement of fluid into the chest, enveloping the lungs. This condition poses challenges to everyday activities such as eating, drinking, and mobility, and it can also impede normal breathing.

 

Ascites Epidemiology Segmentation

  • Number of Ascites Cases due to Cirrhosis
  • Number of Ascites Cases by Malignancies
  • Severity-specific Cases of Ascites due to Cirrhosis 

 

Download the report to understand which factors are driving ascites epidemiology trends @ Ascites Epidemiological Insights

 

Ascites Treatment Market 

The management of ascites resulting from cirrhosis involves various approaches, including the use of diuretics, paracentesis, the placement of a transjugular intrahepatic portosystemic shunt (TIPS), and addressing complications such as spontaneous bacterial peritonitis (SBP). For mild and moderate cirrhotic ascites, treatment encompasses dietary sodium restriction, addressing the underlying condition, fluid restriction, diuretic use, and therapeutic paracentesis. In cases of refractory ascites associated with liver cirrhosis, the strategies involve optimizing medical care, performing serial large volume paracenteses, considering TIPS, peritoneovenous shunt, and exploring the option of liver transplantation.

 

Learn more about the FDA-approved drugs for ascites @ Drugs for Ascites Treatment

 

Key Ascites Therapies and Companies

The mid-stage developments of the ascites pipeline feature promising pharmaceuticals that are poised for approval shortly. Key contributors such as Ocelot Bio, Inc., along with other notable entities, can bring about a substantial positive change in the size of the ascites market. 

Ocelot Bio, Inc. is in the process of developing OCE-205, a therapy under investigation aimed at revolutionizing the treatment of end-stage liver disease (ESLD). The company is also exploring the potential of OCE-205 for addressing ascites, a complication arising from ESLD-induced portal hypertension that results in the accumulation of fluid in the peritoneal cavity. Ascites significantly reduce the quality of life and serve as an indicator of a more challenging prognosis for individuals grappling with ESLD. Presently, the company is engaged in a Phase II multi-center, randomized, placebo-controlled, double-blind, adaptive dose-ranging study to evaluate the safety and effectiveness of intravenous OCE-205 in adults diagnosed with cirrhosis with ascites, particularly those who have developed hepatorenal syndrome-acute kidney injury (HRS-AKI).

 

To know more about ascites clinical trials, visit @ Ascites Drugs

 

Ascites Market Dynamics

The ascites market dynamics are anticipated to change in the coming years. The rise in the patient population with underlying conditions such as liver cirrhosis, alcoholism, kidney or heart failure, malignancy, etc., may contribute to an increase in the incidence of ascites. The growing healthcare activities and campaigns emphasizing the importance of addressing ascites are bolstering the market. The Serum-Ascites Albumin Gradient plays a crucial role in accurately differentiating ascites fluid, achieving a 90% accuracy rate, and successfully identifying the underlying conditions. 

 

Scope of the Ascites Market Report

  • Ascites Therapeutic Assessment: Ascites current marketed and emerging therapies
  • Ascites Market Dynamics: Attribute Analysis of Emerging Ascites Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Ascites Market Access and Reimbursement

 

Discover more about ascites drugs in development @ Ascites Clinical Trials

 

Table of Contents

1. Key Insights

2. Executive Summary of Ascites

3. Competitive Intelligence Analysis for Ascites

4. Ascites: Market Overview at a Glance

5. Ascites: Disease Background and Overview

6. Patient Journey

7. Ascites Epidemiology and Patient Population

8. Ascites Treatment Algorithm, Current Treatment, and Medical Practices

9. Ascites Unmet Needs

10. Key Endpoints of Ascites Treatment

11. Ascites Marketed Products

12. Ascites Emerging Therapies

13. Ascites: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Ascites Market Outlook

16. Ascites Market Access and Reimbursement Overview

17. Ascites KOL Views

18. Ascites Market Drivers

19. Ascites Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ascites Market is expected to grow by 2032, estimates DelveInsight

Venous Thromboembolism Market is expected to grow by 2032, estimates DelveInsight

DelveInsight’s “Venous Thromboembolism Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Venous Thromboembolism Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

 

Request for Sample Report @ Venous Thromboembolism Market Size Report

 

Venous Thromboembolism: An Overview

Venous Thromboembolism (VTE) is a disorder that includes Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) . A deep vein thrombosis (DVT) occurs when a blood clot forms in a deep vein, usually in the lower leg, thigh, or pelvis. A deep vein thrombosis may occur if the flow of blood slows down in the body’s deep veins. A pulmonary embolism (PE) occurs when a clot breaks loose and travels through the bloodstream to the lungs.

 

Venous Thromboembolism Market Key Facts

  • As per the study by Ota et al., (2015), titled “Incidence, Characteristics and Management of Venous Thromboembolism in Japan During 2011,”, nearly 16,096 and 24,538 individuals in Japan were diagnosed with new PE and DVT, respectively, during 2011, which represented overall annual incidences of 12.6 and 19.2 per 100,000,  respectively.
  • A multinational report of European Union countries estimated that the total number of symptomatic, nonfatal VTE events per annum was more than 465,000 cases of DVT and more than 295,000 cases of PE. 

 

Venous Thromboembolism Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Venous Thromboembolism market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report details the Venous Thromboembolism market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

 

Request for Sample PDF Report – Venous Thromboembolism Market Outlook Report

 

Venous Thromboembolism Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

 

Venous Thromboembolism Epidemiology Segmentation

  • Total Incident Cases 
  • Total Diagnosed Cases 
  • Type-specific Cases 
  • Total Age-specific Cases 
  • Occurrence-specific Cases 
  • Total Prophylactic/Preventive Setting Cases 
  • Total Potential (Mortality and Recurrent adjusted) Cases 
  • Total Treated Cases of VTE for Treatment and Prophylactic Settings

 

Request for Sample Report @ Venous Thromboembolism Market Forecast

 

Venous Thromboembolism Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Venous Thromboembolism market or expected to get launched during the study period. The analysis covers Venous Thromboembolism market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Venous Thromboembolism Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Venous Thromboembolism Therapeutics Analysis

The Venous Thromboembolism market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the diseases, and incremental healthcare spending worldwide.

 

Key Companies in the Venous Thromboembolism Market include:

  • Ionis Pharmaceuticals
  • Bristol-Myers Squibb 
  • Janssen Pharmaceuticals
  • Quercis Pharmaceuticals
  • Ono Pharmaceutical
  • Verseon Corporation
  • Bayer Pharmaceuticals

 

Venous Thromboembolism Therapies covered in the report include:

  • ONO-7684
  • Milvexian
  • Isoquercetin
  • VE-1902
  • IONIS-FXI-LRx
  • Osocimab (BAY 1213790) 

 

Get More Detailed Insights Into the Emerging Therapies & Key Companies – Venous Thromboembolism Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary 

3. Venous Thromboembolism Competitive Intelligence Analysis

4. Venous Thromboembolism Market Overview at a Glance

5. Venous Thromboembolism Disease Background and Overview

6. Venous Thromboembolism Patient Journey

7. Venous Thromboembolism Epidemiology and Patient Population

8. Venous Thromboembolism Treatment Algorithm, Current Treatment, and Medical Practices

9. Venous Thromboembolism Unmet Needs

10. Key Endpoints of Venous Thromboembolism Treatment

11. Venous Thromboembolism Marketed Products

12. Venous Thromboembolism Emerging Therapies

13. Venous Thromboembolism Seven Major Market Analysis

14. Attribute Analysis

15. Venous Thromboembolism Market Outlook (7 major markets)

16. Venous Thromboembolism Access and Reimbursement Overview

17. KOL Views on the Venous Thromboembolism Market.

18. Venous Thromboembolism Market Drivers

19. Venous Thromboembolism Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

Get in touch with us regarding this report @ Venous Thromboembolism Market Drivers and Barriers

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Venous Thromboembolism Market is expected to grow by 2032, estimates DelveInsight

Postoperative Acute Pain in the US is expected to increase by 2032 during the study period (2019 – 2032) at a CAGR of 7.9%.

DelveInsight’s Postoperative Acute Pain Market Insights report includes a comprehensive understanding of current treatment practices, postoperative acute pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into the United States.

 

Key Takeaways from the Postoperative Acute Pain Market Report

  • According to DelveInsight’s analysis, the market size for postoperative acute pain in the US is expected to grow with a significant 7.9% CAGR by 2032.
  • DelveInsight’s analysis reveals that the overall incident population of postoperative pain in the US was reported as ~47 million in 2022. 
  • The US accounted for approximately 44% of moderate and around 30% of severe cases based on severity-specific cases.
  • Leading postoperative acute pain companies such as Taiwan Liposome Company (TLC), Teikoku Pharma, Concentric Analgesics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Avenue Therapeutics, Cali Pharmaceuticals LLC, Bayer, and others are developing novel postoperative acute pain drugs that can be available in the postoperative acute pain market in the coming years.
  • The promising postoperative acute pain therapies in the pipeline include TLC590, TPU-006 (Dexmedetomidine Transdermal System [DMTS]), Vocacapsaicin (CA-008), F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib), SURF-201 (betamethasone 0.2% in KLARITY vehicle), SVT-15473 (clobetasol propionate ophthalmic nanoemulsion 0.05%), VX-548, APP13007 (clobetasol propionate ophthalmic nanosuspension), AVE-901 (IV Tramadol), CPL-01 (ropivacaine hydrochloride), BAY2880376 (naproxen sodium and caffeine), and others.

 

Discover which therapies are expected to grab the major postoperative acute pain market share @ Postoperative Acute Pain Market Size Report

 

Postoperative Acute Pain Overview

Acute postoperative pain is a normal response to surgical intervention. It not only contributes to delayed recovery and extended hospital stay but also elevates the risk of complications such as wound infections and problems related to the respiratory or cardiovascular systems. Failure to address this pain can lead to diminished patient satisfaction, heightened morbidity and mortality rates, and financial burdens. Chronic postsurgical pain (CPSP) is a condition in which acute pain persists and becomes resistant. CPSP is a result of inflammation caused by tissue trauma or direct nerve injury, and it can be categorized as either nociceptive or neuropathic. 

 

Postoperative Acute Pain Epidemiology Segmentation

  • Total Postoperative Acute Pain Incident Cases
  • Postoperative Acute Pain Visit-specific Surgical Cases
  • Postoperative Acute Pain Severity-specific Cases

 

Postoperative Acute Pain Treatment Market 

The objective of postoperative pain management is not just to reduce pain intensity but also to enhance patient comfort and improve postoperative outcomes. Effective pain control involves employing various combinations of regional analgesic techniques and the systemic administration of analgesic agents. Pharmacological approaches to pain relief encompass medications from diverse drug classes. These include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen. Additionally, healthcare providers may choose to address acute pain using benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric agonists, and cannabinoids. 

 

To know more about postoperative acute pain treatment guidelines, visit @ Postoperative Acute Pain Management

 

Postoperative Acute Pain Pipeline Therapies and Key Companies

  • TLC590: Taiwan Liposome Company (TLC)
  • TPU-006 (Dexmedetomidine Transdermal System [DMTS]): Teikoku Pharma
  • Vocacapsaicin (CA-008): Concentric Analgesics
  • F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib): Arthritis Innovation Corporation/MedinCell
  • SURF-201 (betamethasone 0.2% in KLARITY vehicle): Surface Ophthalmics
  • SVT-15473 (clobetasol propionate ophthalmic nanoemulsion 0.05%): Salvat Laboratories
  • VX-548: Vertex Pharmaceuticals
  • APP13007 (clobetasol propionate ophthalmic nanosuspension): Formosa Pharmaceuticals
  • OCS-01 (dexamethasone cyclodextrin nanoparticle ophthalmic suspension 1.5%): Oculis
  • AVE-901 (IV Tramadol): Avenue Therapeutics
  • CPL-01 (ropivacaine hydrochloride): Cali Pharmaceuticals LLC
  • BAY2880376 (naproxen sodium and caffeine): Bayer

 

Learn more about the FDA-approved drugs for postoperative acute pain @ Drugs for Postoperative Acute Pain Treatment

 

Postoperative Acute Pain Market Dynamics

The dynamics of the postoperative acute pain market are expected to change in the coming years. One crucial driver is the rising number of surgical procedures globally, leading to an increased prevalence of postoperative acute pain. The growing awareness about pain management and the importance of patient comfort post-surgery has prompted healthcare providers to adopt advanced and efficient pain management solutions, thereby boosting the postoperative acute pain market.

 

Scope of the Postoperative Acute Pain Market Report

  • Therapeutic Assessment: Postoperative Acute Pain current marketed and emerging therapies
  • Postoperative Acute Pain Market Dynamics: Key Market Forecast Assumptions of Emerging Postoperative Acute Pain Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Postoperative Acute Pain Market Access and Reimbursement

 

Discover more about postoperative acute pain drugs in development @ Postoperative Acute Pain Clinical Trials

 

Table of Contents

1. Key Insights

2. Report Introduction

3. Postoperative Acute Pain Market Overview at a Glance

4. Executive Summary of Postoperative Acute Pain

5. Key Events

6. Disease Background and Overview

7. Treatment

8. Methodology

9. Epidemiology and Patient Population

10. Patient Journey

11. Marketed Therapies

12. Emerging Therapies

13. Postoperative Acute Pain – US Market Analysis

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

Get in touch with us regarding this report @ Postoperative Acute Pain Market Drivers and Barriers

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Postoperative Acute Pain in the US is expected to increase by 2032 during the study period (2019 – 2032) at a CAGR of 7.9%.

The Fabry Disease Market is expected to grow by factors like an increase in the patient pool, and expected entry of emerging therapies

DelveInsight’s Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

 

Key Takeaways from the Fabry Disease Market Research Report

  • The total Fabry Disease market size in the 7MM is approximately USD 1,306 million in 2022 and is projected to increase during the forecast period (2023-2032)
  • Among EU countries, the UK and Italy account for the maximum market size of USD 158, and USD 150 million in 2022 while Spain occupies the bottom of the ladder in the same year with USD 44 million.
  • Japan accounts for a market size of USD 125 million in 2022, but these dynamics are expected to change in the forecast period.
  • There were 15,200+ diagnosed prevalent cases of Fabry Disease estimated to have occurred in the 7MM in 2022 of which 8,300+ of the accounted cases were estimated to be from the US alone and these cases are anticipated to increase during the forecast period.
  • The diagnosed prevalent cases of Fabry Disease were further divided into Phenotype-specific cases. The Phenotype-specific diagnosed prevalent cases of Fabry Disease are categorized into Classic and Late-onset with 6,900+, and 8,300+ cases respectively in the 7MM in 2022 which will further increase in 2032.

 

Discover which therapies are expected to grab the major Fabry disease market share @ Fabry Disease Market Size Report

 

Fabry Disease Overview

Fabry disease is an inherited lysosomal storage disorder caused by a nonfunctional or partially functional enzyme called alpha-galactosidase A (-Gal A). Reduced -Gal A activity in lysosomes leads to the accumulation of enzyme substrates (Gb3 and lyso-Gb3), which causes cellular damage in tissues throughout the body. Despite being X-linked, heterozygous women may experience all of the signs and symptoms seen in men; however, when compared to hemizygous males, the signs and symptoms of Fabry disease in women typically appear later and with less severity.

 

Fabry Disease Epidemiology Segmentation

  • Prevalent Cases of Fabry Disease
  • Age-specific Cases of Fabry Disease
  • Gender-specific Cases of Fabry Disease
  • Diagnosed Cases of Fabry Disease
  • Phenotype-specific cases
  • Treated Cases

 

Download the report to understand which factors are driving Fabry disease epidemiology trends @ Fabry Disease Epidemiological Insights

 

Fabry Disease Treatment Market

Fabry disease treatment includes enzyme replacement therapy (ERT), oral chaperone therapy, and adjunctive treatment such as ACE inhibitors or angiotensin receptor blockers, antiplatelet drugs, and analgesics. Studies have shown ERT to delay, but not always prevent, some clinical complications of FD. Currently, effective Fabry disease management necessitates a multidisciplinary approach that includes intravenous ERT or chaperone therapy, as well as adjunct therapies such as lifestyle modifications and prophylactic medications.

 

Fabry Disease Pipeline Therapies and Key Companies

  • PRX-102 (Pegunigalsidase Alfa): Protalix Biotherapeutics
  • Venglustat: Sanofi Genzyme
  • ST-920: Sangamo Therapeutics
  • FLT190: Freeline Therapeutics
  • 4D-310: 4D Molecular Therapeutics
  • Lucerastat: Idorsia Pharmaceuticals
  • Moss-aGal: GREENOVATION BIOTECH GMBH

 

To know more about Fabry disease medication, visit @ Fabry Disease Treatment Market

 

Fabry Disease Market Dynamics

To counter the current unmet needs of the Fabry disease market and to provide better treatment options, several companies are working aggressively to develop new therapies with novel mechanisms of action. In addition, many therapies are being studied in various stages of clinical trials. Pegylated forms of -GAL, gene therapy, and substrate reduction therapy are examples of these. 

 

Learn more about the FDA-approved drugs for Fabry disease treatment @ Drugs for Fabry Disease Treatment

 

Scope of the Fabry Disease Market Report

  • Therapeutic Assessment: Fabry Disease’s current marketed and emerging therapies
  • Fabry Disease Market Dynamics: Fabry Disease market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement

 

Discover more about drugs for Fabry disease in development @ Fabry Disease Clinical Trials

 

Table of Content

1. Key Insights

2. Fabry Disease Market Report Introduction

3. Fabry Disease Market Overview At A Glance

4. Fabry Disease Epidemiology And Market Forecast Methodology

5. Key Events

6. Executive Summary Of Fabry Disease

7. Fabry Disease Market Disease Background And Overview

8. Fabry Disease Epidemiology And Patient Population

9. Fabry Disease Patient Journey

10. Fabry Disease Marketed Drugs

11. Fabry Disease Emerging Drugs

12. Fabry Disease: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. Fabry Disease Swot Analysis

15. Fabry Disease Unmet Needs

16. Fabry Disease Market Access And Reimbursement

17. Appendix

18. Delveinsight Capabilities

19. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Fabry Disease Market is expected to grow by factors like an increase in the patient pool, and expected entry of emerging therapies

The Tendinopathy Market is expected to grow by factors like an increase in the patient pool, and expected entry of emerging therapies

DelveInsight’s Tendinopathy Market Insights report includes a comprehensive understanding of current treatment practices, tendinopathy emerging drugs, market share of individual therapies, and current and forecasted tendinopathy market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

 

Key Takeaways from the Tendinopathy Market Report

  • As per DelveInsight’s analysis, the tendinopathy market is anticipated to grow at a significant CAGR by 2032.
  • According to DelveInsight’s analysis, tendinopathy incidence in the United States has shown an increasing trend. As per the estimates, the United States accounted for ~12 million incident cases in 2022.
  • Leading tendinopathy companies such as Novartis, SynOx Therapeutics Limited, Abbisko Therapeutics Co, Ltd, AmMax Bio, Inc., Deciphera Pharmaceuticals LLC, and others are developing novel tendinopathy drugs that can be available in the tendinopathy market in the coming years.
  • Some of the key therapies for tendinopathy treatment include NGI226, Emactuzumab, ABSK021, AMB-05X, DCC-3014, AIN457, and others.

 

Discover which therapies are expected to grab the tendinopathy market share @ Tendinopathy Market Report

 

Tendinopathy Overview

Tendinopathy represents a compromised healing process within the tendon, marked by the chaotic growth of tenocytes, irregularities within tenocyte cells, the disruption of collagen fibers, and a subsequent rise in the non-collagenous matrix. Tendinopathy is a broad term used to describe clinical conditions associated with overuse in and around tendons, encompassing both pain and pathological characteristics.

 

Tendinopathy Epidemiology Segmentation

  • Total Incident Cases of Tendinopathy
  • Gender-specific Incident Cases of Tendinopathy
  • Type-specific Incident Cases of Tendinopathy
  • Region-specific Incident Cases of Tendinopathy
  • Total Treated Cases of Tendinopathy

 

Download the report to understand which factors are driving tendinopathy epidemiology trends @ Tendinopathy Epidemiological Insights

 

Tendinopathy Treatment Market 

The primary objectives of tendinopathy treatment involve alleviating symptoms, particularly pain, facilitating tendon recovery, and enhancing patient functionality. A variety of therapeutic options are available, such as rest, cold therapy, eccentric exercises, nutraceuticals, ultrasound therapy, sclerosing injections, extracorporeal shockwave therapy, splinting, taping, cryotherapy, electrotherapy, glyceryl trinitrate patches, nonsteroidal anti-inflammatory drugs (NSAIDs), and peritendinous injections. Surgical intervention is typically considered a last resort for persistent tendinopathy cases after exploring all non-operative alternatives. Nevertheless, conservative measures remain the cornerstone of treatment for most tendinopathies.

 

Learn more about the FDA-approved drugs for tendinopathy @ Drugs for Tendinopathy Treatment

 

Key Tendinopathy Therapies and Companies

  • NGI226: Novartis
  • Emactuzumab: SynOx Therapeutics Limited
  • ABSK021: Abbisko Therapeutics Co, Ltd
  • AMB-05X: AmMax Bio, Inc.
  • DCC-3014: Deciphera Pharmaceuticals LLC
  • AIN457: Novartis

 

To know more about tendinopathy clinical trials, visit @ Tendinopathy Drugs

 

Tendinopathy Market Dynamics

The tendinopathy market dynamics are anticipated to change in the coming years. Preclinical models have given credence to this emerging therapeutic modality, and compared to scaffolds and growth factors, there is a paucity of clinical studies using stem cells for augmentation of tendon repair or for treating tendinopathy. Gene therapy is a promising method for facilitating the trafficking of growth factors to the injured site, potentially allowing sustained temporal delivery, while novel mini-invasive procedures that target underlying pathology, such as abnormal neoinnervation, are being developed and are initially promising.

 

Scope of the Tendinopathy Market Report

  • Tendinopathy Therapeutic Assessment: Tendinopathy current marketed and emerging therapies
  • Tendinopathy Market Dynamics: Attribute Analysis of Emerging Tendinopathy Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Tendinopathy Market Access and Reimbursement

 

Discover more about Tendinopathy drugs in development @ Tendinopathy Clinical Trials

 

Table of Contents

1. Key Insights

2. Executive Summary of Tendinopathy

3. Competitive Intelligence Analysis for Tendinopathy

4. Tendinopathy: Market Overview at a Glance

5. Tendinopathy: Disease Background and Overview

6. Patient Journey

7. Tendinopathy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Tendinopathy Unmet Needs

10. Key Endpoints of Tendinopathy Treatment

11. Tendinopathy Marketed Products

12. Tendinopathy Emerging Therapies

13. Tendinopathy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Tendinopathy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Tendinopathy Market is expected to grow by factors like an increase in the patient pool, and expected entry of emerging therapies